This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the current standard of care for high LP(a) and the recent phase 2 results of Amgen's Olpasiran

Ticker(s): AMGN

Who's the expert?

Institution: USC Med center

  • Pediatric Emergency Medicine in practice for more than 20 years in private office 70% and Pediatric ED 30%.
  • Manages about 250 kids with RSV infection in different stages of severity in a year.
  • Familiar with Nirsevimab, and is considering adding it to his practice this RSV season.

 

Interview Goal
olpasiran

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.